Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...
Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein (a) levels by more than 90% for at least six ...
Eli Lilly And Co (NYSE:LLY), on Sunday, announced positive Phase 2 results for lepodisiran, an investigational small ...
An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.
ZME Science on MSN2d
An Experimental Drug Just Slashed Genetic Heart Risk by 94%On Sunday, researchers announced that an experimental drug from Eli Lilly, lepodisiran, reduced levels of Lp (a) by a ...
Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...
Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...
CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...
BMO Capital Markets analysts said the results potentially position lepodisiran as “one of the most durable assets in ...
Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...
Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback